Optimization of laser-induced choroidal neovascularization in African green monkeys

Experimental Eye Research

Volumn 92, Issue 6, 2011, Pages 464-472

  Goody, Robin J ^a   Hu, Wenzheng ^b   Shafiee, Afshin ^b   Struharik, Michael ^a   Bartels, Stephen ^b   López, Francisco J ^b   Lawrence, Matthew S ^a  

^a RxGen Inc   (United States)

^b BAUSCH AND LOMB   (United States)

Author keywords

African green monkey; Age related macular degeneration; Animal model; Chlorocebus sabaeus; Laser induced choroidal neovascularization; Nonhuman primate; VEGF

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLOROCEBUS; CONTROLLED STUDY; DENSITOMETRY; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; LASER; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BRUCH MEMBRANE; CERCOPITHECUS AETHIOPS; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FLUORESCEIN ANGIOGRAPHY; LASER COAGULATION; MACULA LUTEA; MALE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 79956337946     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.03.006     Document Type: Article

References (32)

1. Barany E. Applanation tonometry and ophthalmoscopy of the vervet monkey (Cercopithecus aethiops) in phencyclidine catalepsia. Invest. Ophthalmol. 1963, 2:322-324.
2. Barany E.H. Pilocarpine-induced subsensitivity to carbachol and pilocarpine of ciliary muscle in vervet and cynomolgus monkeys. Acta Ophthalmol. (Copenh) 1977, 55:141-163.
3. Campa C., Kasman I., Ye W., Lee W.P., Fuh G., Ferrara N. Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes. Invest. Ophthalmol. Vis. Sci. 2008, 49:1178-1183.
4. Carlsson H.E., Schapiro S.J., Farah I., Hau J. Use of primates in research: a global overview. Am. J. Primatol. 2004, 63:225-237.
5. Ciulla T.A., Rosenfeld P.J. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 2009, 20:158-165.
6. Francois J., De Laey J.J., Cambie E., Hanssens M., Victoria-Troncoso V. Neovascularization after argon laser photocoagulation of macular lesions. Am. J. Ophthalmol. 1975, 79:206-210.
7. Green W.R. Histopathology of age-related macular degeneration. Mol. Vis. 1999, 5:27.
8. Hu W., Criswell M.H., Fong S.L., Temm C.J., Rajashekhar G., Cornell T.L., Clauss M.A. Differences in the temporal expression of regulatory growth factors during choroidal neovascular development. Exp. Eye Res. 2009, 88:79-91.
9. Husain D., Kim I., Gauthier D., Lane A.M., Tsilimbaris M.K., Ezra E., Connolly E.J., Michaud N., Gragoudas E.S., O'Neill C.A., Beyer J.C., Miller J.W. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch. Ophthalmol. 2005, 123:509-516.
10. Kim I.K., Husain D., Michaud N., Connolly E., Lane A.M., Durrani K., Hafezi-Moghadam A., Gragoudas E.S., O'Neill C.A., Beyer J.C., Miller J.W. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest. Ophthalmol. Vis. Sci. 2006, 47:357-363.
11. Koh H.J., Freeman W.R., Azen S.P., Flaxel C.J., Labree L.D., Cheng L., Wills M., Jones T.R. Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey. Retina 2006, 26:202-209.
12. Krzystolik M.G., Afshari M.A., Adamis A.P., Gaudreault J., Gragoudas E.S., Michaud N.A., Li W., Connolly E., O'Neill C.A., Miller J.W. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 2002, 120:338-346.
13. Kwak N., Okamoto N., Wood J.M., Campochiaro P.A. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2000, 41:3158-3164.
14. Lai C.C., Wu W.C., Chen S.L., Xiao X., Tsai T.C., Huan S.J., Chen T.L., Tsai R.J., Tsao Y.P. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 2001, 42:2401-2407.
15. Lichtlen P.D., Lam T., Nork M., Streit T., Urech D.M. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing efficacy of bevacizumab, adalimumab and ESBA105. Invest. Ophthalmol. Vis. Sci. 2010, 51:4738-4745.
16. Lu F., Adelman R.A. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?. Graefes Arch. Clin. Exp. Ophthalmol. 2009, 247:171-177.
17. Marano R.J., Rakoczy P.E. An improved method using densitometry for evaluating severity of laser photocoagulation induced CNV. Biotech. Histochem. 2006, 81:59-62.
18. Marano R.J., Toth I., Wimmer N., Brankov M., Rakoczy P.E. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther. 2005, 12:1544-1550.
19. Merrill N.L., Burge R. Effects of three mydriatic drug regimens on pupil size in rhesus (Macaca mulatta) and African green monkeys (Chlorocebus aethiops). J. Med. Primatol. 2007, 36:33-38.
20. Miller J.W., Walsh A.W., Kramer M., Hasan T., Michaud N., Flotte T.J., Haimovici R., Gragoudas E.S. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch. Ophthalmol. 1995, 113:810-818.
21. Ozkiris A. Anti-VEGF agents for age-related macular degeneration. Expert Opin. Ther. Pat. 2010, 20:103-118.
22. Resnikoff S., Pascolini D., Etya'ale D., Kocur I., Pararajasegaram R., Pokharel G.P., Mariotti S.P. Global data on visual impairment in the year 2002. Bull. World Health Organ. 2004, 82:844-851.
23. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431.
24. Ryan S.J. The development of an experimental model of subretinal neovascularization in disciform macular degeneration. Trans. Am. Ophthalmol. Soc. 1979, 77:707-745.
25. Ryan S.J. Subretinal neovascularization. Natural history of an experimental model. Arch. Ophthalmol. 1982, 100:1804-1809.
26. Shen W.Y., Garrett K.L., Wang C.G., Zhang K., Ma Z.Z., Constable I.J., Rakoczy P.E. Preclinical evaluation of a phosphorothioate oligonucleotide in the retina of rhesus monkey. Lab. Invest. 2002, 82:167-182.
27. Shen W.Y., Lee S.Y., Yeo I., Lai C.M., Mathur R., Tan D., Constable I.J., Rakoczy P.E. Predilection of the macular region to high incidence of choroidal neovascularization after intense laser photocoagulation in the monkey. Arch. Ophthalmol. 2004, 122:353-360.
28. Takahashi H., Obata R., Tamaki Y. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. J. Ocul. Pharmacol. Ther. 2006, 22:213-218.
29. Tolentino M.J., Husain D., Theodosiadis P., Gragoudas E.S., Connolly E., Kahn J., Cleland J., Adamis A.P., Cuthbertson A., Miller J.W. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch. Ophthalmol. 2000, 118:78-84.
30. Yanagi Y., Tamaki Y., Obata R., Muranaka K., Homma N., Matsuoka H., Mano H. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest. Ophthalmol. Vis. Sci. 2002, 43:3495-3499.
31. Yu L., Wu X., Cheng Z., Lee C.V., LeCouter J., Campa C., Fuh G., Lowman H., Ferrara N. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest. Ophthalmol. Vis. Sci. 2008, 49:522-527.
32. Zhang M., Yan M., Wang L., Zhang J.J., Liu B., Meng D., Du C.F. Experimental choroidal neovascularization induced by laser in the eyes of rhesus monkeys. Sichuan Da Xue Xue Bao Yi Xue Ban 2008, 39. pp. 567-569, 574.